American Society of Hirudotherapy

Plantar Fibromatosis (Ledderhose Disease)

Investigational use for plantar fascia nodules in early Ledderhose disease; no clinical study of leech therapy for this condition was identified.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for plantar fibromatosis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for Ledderhose disease is investigational.
What evidence exists?
No published clinical study of leech therapy could be verified for this condition. Tier C (investigational). Established options for symptomatic plantar fibromatosis include custom orthotic accommodation (first-line), low-dose radiotherapy for early disease, and surgical excision for advanced disease (with high recurrence rates and risk of plantar nerve injury). Most asymptomatic nodules require only observation.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness on the plantar surface
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Worsening pain after the procedure (transient)
  • Risk if a leech is placed too close to a plantar nerve or rupture site
  • Difficulty bearing weight for several days after treatment
  • Delay of orthotic accommodation, radiotherapy, or surgical evaluation
Who should not consider this
  • Patients with active plantar fascial rupture or ulceration
  • Patients with diabetic peripheral neuropathy (reduced protective sensation at bite site)
  • Patients with peripheral arterial disease severe stenosis (ABI <0.6)
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Pregnant patients
  • Patients who have not tried custom orthotic accommodation
What to ask your clinician
  • Have I tried custom orthotic accommodation and activity modification?
  • Have I been evaluated for low-dose radiotherapy in early-stage disease?
  • Is my diabetic foot exam normal (sensation, pulses, ABI)?
  • What evidence specifically supports leech therapy for plantar fibromatosis?
  • Are leeches from an FDA-registered supplier and used only once?
  • What is the practitioner's Aeromonas-prevention plan?
  • What is the cost and is it covered by insurance? (typically not covered)
When to seek urgent care
  • Inability to bear weight or new severe foot pain after treatment
  • Numbness or tingling in the foot (possible nerve injury)
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

What this does NOT mean

  • This is NOT FDA-cleared for plantar fibromatosis.
  • With no clinical study identified, efficacy versus orthotic accommodation, low-dose radiotherapy, or surgical excision is untested.
  • It does NOT cure Ledderhose disease — recurrence is common.
  • It does NOT replace a thorough diabetic foot exam before any lower-extremity procedure.
  • It does NOT substitute for orthopedic or podiatric evaluation in symptomatic disease.

Clinical Profile

Category
Musculoskeletal
ICD-10
M72.2
Safety tier
Low

Evidence Summary

Plantar fibromatosis (Ledderhose disease), the plantar analogue of Dupuytren's disease, has limited conservative options. No clinical study of leech therapy for plantar fibromatosis (controlled trial, case series or case report) was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov, or Russian- and German-language searches, so there is no evidence of pain reduction or nodule softening. Any proposed antifibrotic mechanism is speculative and unproven. Established large or symptomatic nodules may require radiotherapy or surgical excision (which carries a high recurrence rate), and custom orthotic accommodation can help with footwear tolerance. ASH position: any use of leech therapy for plantar fibromatosis is investigational and mechanistic only.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active plantar fascial rupture or ulceration
  • Diabetic peripheral neuropathy

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.